Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II osimertinib in EGFR-mutant advanced non-small-cell lung carcinoma detected by liquid biopsy
jRCT2080225059Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Center Hospital East. Started Feb 2020; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225059.